in patients with a functioning graft remains high compared to the general population. 1 Left ventricular (LV) hypertrophy is an independent risk factor for morbidity and mortality in both the general population and in patients with ESRD 5 and is present in 75% of patients with ESRD receiving maintenance hemodialysis. 6 This high prevalence is multifactorial resulting from comorbid conditions, such as hypertension and diabetes, and the frequent hemodynamic changes experienced during maintenance hemodialysis. 5 The increased LV mass in ESRD patients secondary to myocardial hypertrophy is a function of an enlargement of the LV end-diastolic diameter and increased LV wall thickness.
While several reports indicate that LV mass improves following kidney transplant, [7] [8] [9] [10] [11] [12] [13] this has not been universally observed in all kidney transplant patients.
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Left ventricular mass has been shown to be directly correlated with fibroblast growth factor (FGF-23). [19] [20] [21] [22] [23] An increased circulating level of FGF-23 is an independent risk factor for cardiovascular disease and mortality, 24, 25 and a supraphysiologic level of has been observed to be independently associated with increased LV mass in patients with chronic kidney disease. [19] [20] [21] [22] [23] 26 Following kidney transplantation, FGF-23 levels decrease concurrently with improved kidney function. Persistently elevated levels of FGF-23
following transplant have been reported to be independently associated with all cause mortality and allograft loss in kidney transplant patients. 24 Limited data regarding the relationship between decreasing FGF-23 levels and changes in LV mass following kidney transplantation exist.
Our aim was to evaluate the longitudinal changes in cardiac morphology and function in a cohort of patients following kidney transplantation. In addition, we evaluated FGF-23 concentration following transplant to investigate a potential association between FGF-23 levels and the evolution of cardiac morphology and function. We hypothesized that cardiac morphology and function assessed by echocardiogram would improve following kidney transplantation in patients with functioning allografts, and longitudinal reduction in FGF-23 levels would be associated with these improvements.
| METHODS

| Study design
We conducted a single-center, prospective cohort study. Patients in the cohort were followed up at 1 month following kidney transplantation, which served as the initial visit for documentation regarding demographic, medical and social history, laboratory values, and echocardiography evaluation for the longitudinal study.
Follow-up visits were performed at 12 and 24 months. All patients gave informed consent, and the VUMC Institutional Review Board approved the study protocol. 
| Echocardiography
| Ejection fraction
The cardiac function was evaluated by the biplane method by measuring the end-diastolic volume (EDV) and end-systolic volume (ESV).
Ejection fraction was calculated by the following formula: (EDV-ESV)/
EDV. An abnormal ejection fraction was defined as <55%. 
| Fibroblast growth factor-23 measurement
| Outcomes
The primary outcome was defined as the change in LV mass index from baseline (1 month post-transplant) to the 12-month follow-up. were included in the models as nonlinear terms using restricted cubic splines. Cardiovascular disease was defined as a baseline history of coronary artery disease, myocardial infarction, reperfusion (coronary artery bypass or percutaneous stent), congestive heart failure, arrhythmia, stroke, or peripheral vascular disease.
| Statistical analysis
A linear mixed-effects model with random intercepts was also used to examine the change in FGF-23 concentrations over time with and without adjustment for age, race, sex, MAP, cardiovascular disease, and eGFR. To meet the normality assumptions of the residuals, FGF-23 concentrations were natural logarithmically transformed. All covariates for models were chosen a priori. Analyses were performed using R, version 3.1.2 (http://www.r-project.org/). The 5% significance level (2 sided) was used.
| RESULTS
| Patient demographic and other characteristics
The study cohort included 143 patients who underwent 1-month evaluation following kidney transplantation. Demographic and other patient characteristics are presented in Table 1 . The cohort (mean age 49±13 years) was 73% male and 75% white. One hundred and thirtysix patients (95%) reported to have hypertension, and 39% and 38%
of the cohort had a history of cardiovascular disease and diabetes, respectively. Three percent of the cohort was taking angiotensin converting enzyme inhibitors, 3% angiotensin receptor blockers, and 57% of beta-blockers at the initial evaluation. At 12 months, 6% were taking angiotensin converting enzyme inhibitors, 11% angiotensin receptor blockers, and 46% beta-blockers. At 24 months, 5% were taking angiotensin converting enzyme inhibitors, 24% angiotensin receptor blockers, and 45% beta-blockers. The median eGFR at 1-month, 12-month, and 24-month follow-up was 57 mL/min/m 2 , 59 mL/min/m 2 , and 57 mL/min/m 2 , respectively. The MAP was 96 mmHg at both the initial evaluation and 12-month evaluation and was 98 mmHg at the 24-month follow-up.
The flowchart of the longitudinal follow-up of the study cohort including the detailed reasons for study dropout is shown in Figure 1 .
An analysis (for details, see Table S1 ) comparing selected characteristics of the patients who returned for follow-up and the 41% of patients who did not remain in the study through the 12-month evaluation showed no significant differences between the groups.
The induction and maintenance immunosuppression regimens were relatively standardized at VUMC with minimal immunosuppression changes during the study period. Ninety percent of the study cohort received alemtuzumab for induction. Tacrolimus and mycophenolate were used in 98% and 96% of the cohort, respectively. No patients in the study cohort were taking sirolimus at the 1-month follow-up; however, one patient was transitioned to sirolimus at the 12-month follow-up and one patient was transitioned at the 24-month follow-up. Four patients (3%) took everolimus during the study and had no changes in their immunosuppression regimen during the follow-up period. There were four patients that took cyclosporine at the 1-month follow-up. Three of those patients continued cyclosporine throughout their follow-up, while one patient was transitioned to tacrolimus at the 12-month follow-up. One patient transitioned from tacrolimus to cyclosporine at the 24-month follow-up.
Minimal acute rejection was observed. Two biopsy confirmed acute rejection episodes occurred by the 1-month follow-up period. In addition, two other biopsies confirmed acute rejection episodes were treated between the 1-and 12-month follow-up, and one biopsy confirmed acute rejection episode treated between the 12-and 24-month follow-up.
T A B L E 1 Baseline characteristics of the kidney transplant cohort at 1-month post-transplantation T A B L E 1 (Continued)
Throughout the 2-year study period, there was one major cardiac event (myocardial infarction) that occurred between the 12-and 24-month follow-up. There were a total of six reported events of angina during the data collection period. Three events occurred in the perioperative period prior to the 1-month evaluation, while two events occurred between the 1-month and 12-month follow-up. There was one event reported between the 12-month and 24-month follow-up, and one dysrhythmic event which occurred between the 1-month and 12-month follow-up.
| Primary outcome
The median LV mass index at 1 month and 12 months (Table 2) Values expressed as median (25th, 75th percentiles).
F I G U R E 2 Box plot of left ventricular mass index measured longitudinally in the cohort population following kidney transplantation
| Secondary outcomes
| LV mass index at 24 months
The median LV mass index at 24 months for the cohort was 96 g/m 
| LV mass, ejection fraction, and LA volume index
The median measurements for LV mass, ejection fraction, and LA volume index at baseline, 12 months and 24 months following kidney transplant are described in Table 2 . The change in LV mass, ejection fraction, and LA volume index over time in unadjusted and adjusted models are shown in Table 3 . In the adjusted model, LV mass changed significantly at both 12 months and 24 months (both P values <.05).
Compared to baseline, LV mass decreased by 13 
| RWT and LV mass index
| FGF-23 Levels
Forty-five patients were included in the analysis that measured FGF-23 at 1-month and 24-month follow-up after kidney transplantation ( Figure 3 ). FGF-23 decreased significantly over time (P=.024). In particular, compared to month 1, FGF-23 decreased by 36% at month 24 (95% CI: 7%, 56%).
| Cardiac morphology and FGF-23 level
The relationships between FGF-23 and cardiac morphology and function over time can be reviewed in Table 4 . In the unadjusted model, there was a significant association between FGF-23 and LV mass index (Table 5) . 
| DISCUSSION
The aim of our study was to evaluate the longitudinal change in cardiac morphology and function following kidney transplantation along with FGF-23 levels to gain an improved understanding of the evolution of cardiovascular risk factors in patients with a functioning allograft. In our prospective cohort, our results show that there was a significant improvement in LV mass index, LA volume index, and ejection fraction from baseline to 12 and 24 months following transplantation. We also observed a significant decrease in FGF-23 levels, but this was not associated with LV mass index in adjusted analyses.
In contrast to our primary finding, several prior studies have failed to show a significant improvement in LV mass following kidney transplant. following transplant have a limited cohort size (<45 patients) 8, 10, 29, 30 or are retrospective in study design. 28 Given the long duration of follow-up in our study evaluating a large prospective cohort, our findings strengthen the evidence describing an improvement in LV mass after kidney transplantation. In addition, the conversion from calcineurin inhibitors to sirolimus or everolimus has been shown to be associated with improved LV mass. 31 This potential confounder was mitigated in our study by the minimal use of everolimus (four patients) and sirolimus (two patients) in our study cohort.
The majority of our cohort had either concentric hypertrophy (elevated LV mass index and elevated RWT) or concentric remodeling (normal LV mass index and elevated RWT) at baseline. However, 25%
of males and 32% of females had concentric hypertrophy at month 12, while 56% of males and 68% of females had concentric remodeling. The physiologic shift from LV hypertrophy to LV remodeling is supported by the significant improvement in LV mass index following transplant observed in our analysis. The study cohort also had a low percentage (9%) of patients who developed de novo LV hypertrophy F I G U R E 3 Box plot of the fibroblast growth factor 23 levels measured longitudinally in the cohort population following kidney transplantation a Each outcome was adjusted for age at transplant, race, gender, cardiovascular disease, mean arterial pressure, and estimated glomerular filtration rate. did not return for the 12-month follow-up compared to those who completed the study, suggesting that any bias is likely to be minimal.
However, differences between these two groups in characteristics not examined cannot be ruled out. Furthermore, the echocardiography in the evaluation of LV mass in patients with ESRD can be inaccurate. Cardiac magnetic resonance imaging (cMRI) has been shown to be a superior imaging modality to evaluate cardiac morphology than echocardiograms. 40, 41 The limitation for echocardiography compared to cMRI in assessing LV mass after transplant is that the observed reduction in LV mass seen with echocardiography may be an artifact related to improved intravascular volume. 42 This limitation is minimized as our initial evaluation was performed at 1 month, at which time fluid status should be normalized with a functioning allograft. Furthermore, the reliability of the echocardiogram measurements could have been strengthened by taking the average of the measurements if two ultrasonographers performed the studies rather than one specialist.
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